Cell and Gene Therapy Market Research Report Information by Therapy Type (Cell Therapy and Gene Therapy), Application (Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032
Market Overview
The Cell and Gene Therapy Market size was valued at USD 12.83 billion in 2023 and is projected to grow from USD 15.01 billion in 2024 to USD 67.89 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.12% during the forecast period (2024 - 2032). The growing incidences of cancer and rare disorders and increasing approval for gene and cell therapy products are major factors driving the market growth.
Increasing incidences of diseases such as cancer, cystic fibrosis, sickle cell anaemia, and others, are burgeoning market growth. Thus, the increasing incidences of cancer and rare disorders across the globe and rising innovative product launches to treat these diseases are boosting the growth of the market.
Favorable regulatory authorities play an important role because these treatments are more widely accepted by healthcare professionals, patients, and regulatory bodies. Frequent approval increases the number of patients willing to consider these therapies. Furthermore, there are clear pathways for regulatory approval due to the increased use of cell and gene therapy.
Market Segment Insights
Based on therapy type, the global cell & gene therapy market has been segmented into cell therapy and gene therapy.
Based on application, the global cell & gene therapy market has been segmented into Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders, and Others.
Regional Insight
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.
Based on region, the global cell & gene therapy market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share of 42.68% in 2022 and is anticipated to reach approximately USD 27.01 billion by 2032 at a 17.38% CAGR during the forecast period, owing to rise in the prevalence of chronic disease, availably of reimbursements for the gene therapy and rise in healthcare expenditure and research development activities for gene therapy drugs across the region. In North America, US dominated the market with market share of 82.36%.
However, Asia-Pacific is projected to grow at the highest CAGR of 20.10% during the forecast period, owing to a sizable population base, heightened healthcare awareness, and a surge in cases of cancer. These factors collectively drive the demand for gene therapy in the region. Additionally, pharmaceutical market expansion, government initiatives, and a surge in research and development activities contribute to the region's accelerated growth. Furthermore, a rise in research activities as well as the well-established presence of domestic companies in the region are expected to provide notable opportunities for market growth. Asia-Pacific is further segmented into the China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Japan dominated the market in Asia-Pacific region with market share 24.55%.
Major Players
Key Companies in the Cell and Gene Therapy Market include Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Aurion Biotech (US), Sarepta Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Sibiono Genetech Co, Ltd., Shenzhen (Sibiono), Bluebird Bio, Inc. (US), Kite Pharmaceuticals, Inc. (US), and Janssen Global Services (US).
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 MAJOR CELL AND GENE THERAPY APPROVED PRODUCTS
TABLE 3 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 4 GLOBAL CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY REGION, 2021–2032 (USD MILLION)
TABLE 5 GLOBAL CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2021–2032 (USD MILLION)
TABLE 6 GLOBAL CELL AND GENE THERAPY MARKET, FOR AUTOLOGOUS, BY REGION, 2021–2032 (USD MILLION)
TABLE 7 GLOBAL CELL AND GENE THERAPY MARKET, FOR ALLOGENEIC, BY REGION, 2021–2032 (USD MILLION)
TABLE 8 GLOBAL CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY REGION, 2021–2032 (USD MILLION)
TABLE 9 GLOBAL CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2021–2032 (USD MILLION)
TABLE 10 GLOBAL CELL AND GENE THERAPY MARKET, FOR EX VIVO, BY REGION, 2021–2032 (USD MILLION)
TABLE 11 GLOBAL CELL AND GENE THERAPY MARKET, FOR IN VIVO, BY REGION, 2021–2032 (USD MILLION)
TABLE 12 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 13 GLOBAL CELL AND GENE THERAPY MARKET, FOR CANCER, BY REGION, 2021–2032 (USD MILLION)
TABLE 14 GLOBAL CELL AND GENE THERAPY MARKET, FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2032 (USD MILLION)
TABLE 15 GLOBAL CELL AND GENE THERAPY MARKET, FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021–2032 (USD MILLION)
TABLE 16 GLOBAL CELL AND GENE THERAPY MARKET, FOR RARE DISEASES, BY REGION, 2021–2032 (USD MILLION)
TABLE 17 GLOBAL CELL AND GENE THERAPY MARKET, FOR OPHTHALMOLOGY, BY REGION, 2021–2032 (USD MILLION)
TABLE 18 GLOBAL CELL AND GENE THERAPY MARKET, FOR BLOOD DISORDERS, BY REGION, 2021–2032 (USD MILLION)
TABLE 19 GLOBAL CELL AND GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)
TABLE 20 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION, 2019–2032 (USD MILLION)
TABLE 21 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 22 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 23 NORTH AMERICA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 24 NORTH AMERICA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 25 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 26 US: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 27 US: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 28 US: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 29 US: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 30 CANADA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 31 CANADA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 32 CANADA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 33 CANADA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 34 EUROPE: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 35 EUROPE: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 36 EUROPE: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 37 EUROPE: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 38 EUROPE: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 39 GERMANY: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 40 GERMANY: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 41 GERMANY: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 42 GERMANY: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 43 FRANCE: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 44 FRANCE: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 45 FRANCE: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 46 FRANCE: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 47 UK: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 48 UK: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 49 UK: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 50 UK: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 51 ITALY: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 52 ITALY: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 53 ITALY: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 54 ITALY: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 55 SPAIN: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 56 SPAIN: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 57 SPAIN: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 58 SPAIN: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 59 REST OF EUROPE: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 60 REST OF EUROPE: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 61 REST OF EUROPE: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 62 REST OF EUROPE: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 63 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 64 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 65 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 66 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 67 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 68 CHINA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 69 CHINA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 70 CHINA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 71 CHINA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 72 INDIA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 73 INDIA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 74 INDIA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 75 INDIA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 76 JAPAN: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 77 JAPAN: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 78 JAPAN: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 79 JAPAN: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 80 AUSTRALIA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 81 AUSTRALIA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 82 AUSTRALIA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 83 AUSTRALIA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 84 SOUTH KOREA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 85 SOUTH KOREA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 86 SOUTH KOREA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 87 SOUTH KOREA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 88 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 89 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 90 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 91 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 92 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY REGION, 2019–2032 (USD MILLION)
TABLE 93 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 94 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 95 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 96 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 98 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 99 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 101 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)
TABLE 102 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 103 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)
TABLE 104 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 105 PUBLIC PLAYERS STOCK SUMMARY
TABLE 106 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 107 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 108 COLLABORATION
TABLE 109 AGREEMENT
TABLE 110 EXPANSION
TABLE 111 NOVARTIS AG: PRODUCT OFFERED
TABLE 112 NOVARTIS AG.: KEY DEVELOPMENTS
TABLE 113 BRISTOL-MYERS SQUIBB COMPANY.: PRODUCT OFFERED
TABLE 114 BRISTOL-MYERS SQUIBB COMPANY.: KEY DEVELOPMENTS
TABLE 115 AMGEN INC.: PRODUCT OFFERED
TABLE 116 AURION BIOTECH: PRODUCT OFFERED
TABLE 117 AURION BIOTECH: KEY DEVELOPMENTS
TABLE 118 SAREPTA THERAPEUTICS, INC.: PRODUCT OFFERED
TABLE 119 SAREPTA THERAPEUTICS, INC.: KEY DEVELOPMENTS
TABLE 120 FERRING B.V.: PRODUCT OFFERED
TABLE 121 FERRING B.V.: KEY DEVELOPMENTS
TABLE 122 SIBIONO GENETECH CO. LTD., SHENZHEN (SIBIONO).: PRODUCT OFFERED
TABLE 123 BLUEBIRD BIO, INC.: PRODUCTS OFFERED
TABLE 124 BLUEBIRD BIO, INC.: KEY DEVELOPMENTS
TABLE 125 KITE PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 126 JANSSEN GLOBAL SERVICES: PRODUCTS OFFERED
TABLE 127 JANSSEN GLOBAL SERVICES: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL CELL AND GENE THERAPY MARKET: STRUCTURE
FIGURE 2 GLOBAL CELL AND GENE THERAPY MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CELL AND GENE THERAPY MARKET
FIGURE 6 GLOBAL CELL AND GENE THERAPY MARKET; THERAPY TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 7 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2023 & 2032 (USD MILLION)
FIGURE 8 GLOBAL CELL AND GENE THERAPY MARKET SHARE (%), BY THERAPY TYPE, 2022
FIGURE 9 GLOBAL CELL AND GENE THERAPY MARKET; APPLICATION SEGMENT ATTRACTIVENESS, (USD MILLION)
FIGURE 10 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION)
FIGURE 11 GLOBAL CELL AND GENE THERAPY MARKET SHARE (%), BY APPLICATION, 2022
FIGURE 12 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION, 2022 & 2032 (USD MILLION)
FIGURE 13 GLOBAL CELL AND GENE THERAPY MARKET SHARE (%), BY REGION, 2022
FIGURE 14 NORTH AMEICA MARKET ANALYSIS: CELL AND GENE THERAPY MARKET, 2019-2032 (USD MILLION)
FIGURE 15 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)
FIGURE 16 NORTH AMERICA: CELL AND GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 17 EUROPE MARKET ANALYSIS: CELL AND GENE THERAPY MARKET, 2019-2032 (USD MILLION)
FIGURE 18 EUROPE: CELL AND GENE THERAPY MARKET, BY REGION, 2022 & 2032 (USD MILLION)
FIGURE 19 EUROPE: CELL AND GENE THERAPY MARKET SHARE (%), BY REGION, 2022
FIGURE 20 ASIA-PACIFIC MARKET ANALYSIS: CELL & GENE THERAPY MARKET, 2019-2032 (USD MILLION)
FIGURE 21 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)
FIGURE 22 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 23 REST OF THE WORLD MARKET ANALYSIS: CELL AND GENE THERAPY MARKET, 2019-2032 (USD MILLION)
FIGURE 24 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY REGION, 2022 & 2032 (USD MILLION)
FIGURE 25 REST OT THE WORLD: CELL AND GENE THERAPY MARKET SHARE (%), BY REGION, 2022
FIGURE 26 CELL AND GENE THERAPY MARKET PLAYERS: COMPETITIVE ANALSIS, 2022
FIGURE 27 COMPETITOR DASHBOARD: GLOBAL CELL AND GENE THERAPY MARKET
FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 NOVARTIS AG.: SWOT ANALYSIS
FIGURE 30 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 BRISTOL-MYERS SQUIBB COMPANY.: SWOT ANALYSIS
FIGURE 32 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 SAREPTA THERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 FERRING B.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 FERRING B.V.: SWOT ANALYSIS
FIGURE 36 BLUEBIRD BIO, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 BLUEBIRD BIO, INC.: SWOT ANALYSIS
FIGURE 38 KITE PHARMACEUTICALS, INC.: SWOT ANALYSIS
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們